Fizazi, et al. ARAMIS: Efficacy and safety of darolutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC). ASCO-GU 2019, abstract 140.
Nieuwe ontwikkelingen in RET-fusiegerichte behandeling en diagnostiek bij longkanker
jun 2021 | Longoncologie